FLNA:NASDAQ
카사바 사이언스
US$1.61
arrow_downward
-3.01%(-0.050) 1D
US$1.58
arrow_downward
-1.70% (-0.027)bedtime시간 외 거래
휴장: 4월 24일, 오후 4시 0분 1초 GMT-4 · USD
search
모든 종목 코드
1D
5D
1M
6M
YTD
1Y
5Y
최대
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_autoFLNA의 주요 통계 생성 중...
시가
US$1.66
고가
US$1.67
저가
US$1.60
시가총액
7776.30만
평균 거래량
40.71만
거래량
35.03만
52주 최고가
US$2.27
52주 최저가
US$1.54
EPS
-US$1.88
베타
-0.66
유통 주식수
4830.80만
직원 수
19
뉴스 기사
웹 소스 기반
프로필
Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. The company was developing simufilam, an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
In June 2024, the United States Department of Justice charged an advisor to company, Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was the company's senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Barbier, Burns and Wang. The parties did not admit wrongdoing, but agreed to pay fines of the company $40 million, Barbier $175,000, Burns $85,000, and Wang $50,000. The DOJ dropped the fraud charges against Wang shortly before trial was scheduled to begin in October 2025 without giving a reason. Wikipedia
카사바 사이언스에 관한 정보
CEO-
직원19
창립일1998
본사오스틴, 텍사스, 미국
업종-
웹사이트-